Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2019; 65(1): 74-80


THE INFLUENCE OF URIC ACID ON BONE MINERAL DENSITY IN PARKINSON’S DISEASE

M.A. Bystrytska, N.V. Grygorieva, V.V. Povoroznyuk, T.Yu. Solonenko

    State Institution “D.F. Chebotarev Institute of Gerontology NAMS of Ukraine”, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz65.01.074

Abstract

The effect of uric acid on bone mineral density (BMD) and the course of Parkinson’s disease (PD) were studied in 80 patients aged 50-80 years (39 ones in the control group and 41 persons with PD). Patients with PD have significantly lower uric acid indices compared to control (268.78 ± 57.43 and 301.69 ± 85.45 μmol/l respectively) and it was connected with body mass (r = 0.50, P <0.05) and body mass index (r = 0.35, P <0.05). Unlike the control group, in patients with PD there was a significant positive relationship between uric acid level with BMD of the proximal femur (r = 0.35, P <0.05), upper (r = 0.36, P<0.05) and lower extremities (r = 0.41, P<0.05) and the total body (r = 0.41, P <0.05). Reliable negative connections of the uric acid level and indexes of cognitive functions (according to Unified Parkinson’s disease rating scale) have been established (r = -0.34, P <0.05).

Keywords: uric acid, mineral density of bone tissue, Parkinson’s disease

References

  1. Lin X, Zhao C, Qin A, Hong D, Liu W, Huang K, Mo J, Yu H, Wu S, Fan S. Association between serum uric acid and bone health in general population: a large and multicentre study. Oncotarget. 2015;6(34):35395-403. CrossRef PubMed PubMedCentral
  2.  
  3. Cortese M, Riise T, Engeland A, Ascherio A, Bjørnevik K. Urate and the risk of Parkinson's disease in men and women. Parkinsonism Relat Disord. 2018; 52:76-82. CrossRef PubMed
  4.  
  5. Wen M, Zhou B, Chen YH, Ma ZL, Gou Y, Zhang CL, Yu WF, Jiao L. Serum uric acid levels in patients with Parkinson's disease: A meta-analysis. PLoS One. 2017; 12(3):e0173731. CrossRef PubMed PubMedCentral
  6.  
  7. Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009; 169(9):1064-9. CrossRef PubMed PubMedCentral
  8.  
  9. Kim TH, Lee JH. Serum uric acid and nigral iron deposition in Parkinson's disease: a pilot study. PloS One. 2014; 9(11): e112512. CrossRef PubMed PubMedCentral
  10.  
  11. Lolekha P, Wongwan P, Kulkantrakorn K. Association between serum uric acid and motor subtypes of Parkinson's disease. J Clin Neurosci. 2015; 22(8): 1264-7. CrossRef PubMed
  12.  
  13. Sakuta H, Suzuki K, Miyamoto T, Masayuki M, Numao A, Fujita H, Watanabe Y,Hirata K. Serum uric acid levels in Parkinson's disease and related disorders. Brain Behav. 2017; 7(1):e00598. CrossRef PubMed PubMedCentral
  14.  
  15. Recommendations for the diagnosis and treatment of Parkinson's disease; edited by prof. I. M. Karaban. Kyiv: LLC "Medical journal" Neuronius", 2017:84. [Ukrainian].
  16.  
  17. Tan L, Wang Y, Zhou L, Shi Y, Zhang F, Liu L, Nie S. Parkinson's disease and risk of fracture: a meta-analysis of prospective cohort studies. PLoS One. 2014; 9(4): e94379. CrossRef PubMed PubMedCentral
  18.  
  19. Metta V, Sanchez T, Padmakumar C. Osteoporosis: a hidden nonmotor face of Parkinson's disease. Int Rev Neurobiol. 2017; 134:877-90. CrossRef PubMed
  20.  
  21. vanden Bos F, Speelman A, Samson M, Munneke M, Bloem B, Verhaar H. Parkinson's disease and osteoporosis. Age Ageing. 2013; 42(2):156-62. CrossRef PubMed
  22.   Povoroznyuk V, Bystrytska M, Karaban I, Karasevich N. Gender features of bone mineral density in patients with Parkinson's disease. Pain Joints Spine. 2018; 8(1):161-166. [Ukrainian]. http://dx.doi.org/10.22141/2224- 1507.8.1.2018.130695  
  23. Kistner A, Lhommée E, Krack P. Mechanisms of body weight fluctuations in Parkinson's disease. Front Neurol. 2014; Jun 2;5:84. doi: 10.3389/fneur.2014.00084. CrossRef  
  24. Tanaka K, Ogata S, Tanaka H, Omura K, Honda C; Osaka Twin Research Group, Hayakawa K. The relationship between body mass index and uric acid: a study on Japanese adult twins. Environ Health Prev Med. 2015; 20(5):347-53. CrossRef PubMed PubMedCentral
  25.  
  26. Mocciaa M, Picillob M, Erroc-dR, Vitalee-f C, Longoe K, Ambonie M, Santangelog G, Palladinoh-i R, Capol G, Oreficea G, Baroneb P, Pellecchia MT. Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease. Eur J Neurol. 2015;22:93-8. CrossRef PubMed
  27.  
  28. Yu Z, Zhang S, Wang D, Fan M, Gao F, Sun W, Li Z, Li S. The significance of uric acid in the diagnosis and treatment of Parkinson disease. Medicine (Baltimore). 2017; 96(45): e8502. CrossRef PubMed PubMedCentral
  29.  
  30. Latourte A, Bardin T, Richette P. Uric acid and cognitive decline: a double-edge sword? Curr Opin Rheumatol. 2018; 30(2):183-7. CrossRef PubMed
  31.  
  32. Dubetska GS. Hyperuricemia and structural and functional status of bone tissue (mineral density and quality) in men of all ages. Pain Joints Spine. 2014; 4(16):69-72. [Ukrainian].
  33.  
  34. Povoroznyuk VV, Dubetska GS. Hyperuricemia, body mass index, lipid metabolism indices and bone mineral density in postmenopausal women. Probl osteol. 2013; 16(1):18-21. [Ukrainian].
  35.  
  36. Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71(2):141-50. CrossRef PubMed PubMedCentral
  37.  

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2019.